Arbutus Biopharma

Showing 1 posts of 1 posts found.


Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure

October 4, 2019
Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma

Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …

Latest content